Sep 30, 2022 / 12:00PM GMT
Operator
Good morning. My name is Rocco, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals RELYVRIO FDA approval Conference Call. (Operator Instructions)
Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsey Allen, Head of Investor Relations and Communications. Please proceed.
Lindsey Allen -
Good morning, and thank you for joining us today to discuss the FDA approval of RELYVRIO, previously known as AMX0035 in the U.S. With me on the call are co-CEOs, Josh Cohen and Justin Klee; and Margaret Olinger, Chief Commercial Officer. Chief Financial Officer, Jim Frates, will be joining us for Q&A.
Before we begin, I would like to remind everyone that some of the statements that we make on this call and information presented in the slide deck include forward-looking statements that are based on our current plans and expectations, including with respect to RELYVRIO. Actual events and results could differ materially from
Amylyx Pharmaceuticals Inc RELYVRIO™ FDA Approval Call Transcript
Sep 30, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers